Question 1

What is Guardant360 CDx?

Accepted Answer

Guardant360 CDx is a Other.

Question 2

How often does Guardant360 CDx appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 7 articles.

Question 3

When was Guardant360 CDx first tracked by Ergen?

Accepted Answer

First tracked on Jun 11, 2026.

Question 4

When was Guardant360 CDx last mentioned in news?

Accepted Answer

Last active on Jun 11, 2026.

Question 5

What is Guardant360 CDx's current news sentiment?

Accepted Answer

Aggregate sentiment score: 75 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Guardant360 CDx in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Guardant360 CDx?

Accepted Answer

FDA approves Guardant360 CDx for HERNEXEOS (Jun 11, 2026, 7 articles).

Question 8

How did the "FDA approves Guardant360 CDx for HERNEXEOS" event impact Guardant360 CDx?

Accepted Answer

Guardant360 CDx received FDA approval as a companion diagnostic for HERNEXEOS, expanding its indications and reinforcing its role in personalized lung cancer care. This approval is the 27th CDx indication for the test.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.